The “Tumor Board” module addresses the central role of interdisciplinary tumor boards in the care of patients with oligometastases. The aim is to sustainably improve planning, implementation, and decision-making in the tumor board through structured, digital, and data-driven support, thereby increasing the quality and efficiency of treatment decisions. The module is located in the closed-loop process at the interface between diagnostics, therapy planning, and clinical decision-making. It integrates relevant image, patient, and diagnostic data from various sources, processes it in a structured manner, and makes it available to the tumor board in a context-sensitive manner. The decisions made in the tumor board are then fed back into downstream therapy and evaluation processes and form the basis for continuous learning and optimization.
In terms of content, the module builds on preliminary work carried out by the research campus, in particular on existing digital infrastructures, data models, and initial applications to support clinical decision-making processes. In the third funding phase, the focus is on the integration, expansion, and clinical validation of these approaches in everyday tumor board practice. For patients with oligometastases, this means an improved patient journey: relevant information is available in a complete and structured form, treatment options can be evaluated in an interdisciplinary manner based on guidelines, and decision-making processes become more transparent and comprehensible. This should reduce delays, make treatment decisions more precise, and improve the overall quality of care.
Collaboration between science and industry is a central element of the module. Clinical partners define requirements from everyday care and contribute medical expertise, while industrial partners develop and implement digital solutions and optimize them in terms of scalability, user-friendliness, and integration into existing systems. Development is iterative and application-oriented. Patients are indirectly involved in the research through the systematic consideration of clinical outcomes, the evaluation of care processes, and, in the future, patient-reported endpoints. The goal is the consistent, patient-centered further development of the tumor board process.
The aim of this sub-project is to provide interfaces for integrating clinical data into the c37.TumorBoard. This includes connecting the QIT PACS to the hospital PACS for the integration of diagnostic imaging. Basic clinical data on patients is transferred via patient data interfaces to the HIS. An external data interface also enables the integration of specialized findings and analyses from pathology, diagnostics, and genetics. In addition, a connection to Prometheus/Cockpit is established in order to integrate further relevant data sources into the overall process. The project partners are celsius37, Mannheim University Hospital, Heidelberg University, and MintMedical. In the M²OLIE process, the subproject is located after biopsy, laboratory, and diagnostics. It creates the technical and procedural basis for structured case discussion in the c37.TumorBoard.
The aim of this subproject is to create templates for treatment procedures and to prepare patient presentations for the tumor board in a structured manner. Templates for treatment procedures are being developed to support complete and quality-assured case preparation. In addition, preparations are to be made for the compact presentation in the tumor board in order to enable a clear and efficient presentation of all information relevant to decision-making. The cooperation partners in this project are celsius37, Mannheim University Hospital, and Heidelberg University. In the closed-loop process, the subproject is located between biopsy, laboratory, and diagnostics in the transition to therapy and supports structured therapy planning in the tumor board.
In this subproject, the tumor board process in c37.TumorBoard will be specifically optimized. This includes adapting the registration form with automatic and patient-specific data import of imaging, laboratory, and pathology results via the existing interfaces. The display of imaging within the tumor board is to be optimized, and direct access to all relevant findings is to be available during case discussions. In addition, an ad hoc or asynchronous tumor board application will be developed and integrated into the celsius37 system. This solution enables flexible, time- and location-independent processing of cases, especially via mobile devices such as tablets. This makes interdisciplinary coordination possible even outside of regular tumor board hours, which significantly increases efficiency and response speed in the clinical decision-making process. The project partners are celsius37, Mannheim University Hospital, and Heidelberg University. The subproject is part of the closed-loop process following biopsy, laboratory, and diagnostics in the transition to therapy and optimizes interdisciplinary collaboration and decision-making.
The aim of this subproject is to integrate current national and international treatment guidelines and relevant study information via web links in order to support guideline-based therapy decision-making in the tumor board. As a solution, current German and international treatment guidelines will first be integrated into the system. In addition, links to relevant studies and protocols of ongoing studies will be provided. Based on the structured patient data and findings available, a guideline-based first-line therapy recommendation will be generated automatically during the tumor board meeting. This work package only covers the implementation of a first-line therapy recommendation. There are plans to expand the system to include second-line therapy recommendations in the future. The cooperation partners in this project are celsius37, Mannheim University Hospital, and Heidelberg University. In the closed-loop process, the subproject is located between biopsy, laboratory, and diagnostics in the transition to therapy and optimizes interdisciplinary collaboration and decision-making.
The aim of the subproject is to scientifically evaluate the mobile application, the ad hoc tumor board, the asynchronous tumor board, and the decision-making algorithm using prospective studies and existing patient data. The subproject pursues several approaches:
The cooperation partners in this project are celsius37, Mannheim University Medical Center, and Heidelberg University. In the M²OLIE closed-loop process, the subproject is located between biopsy, laboratory, and diagnostics in the transition to therapy and serves to scientifically validate digital decision support before the start of therapy.
